Author:
Hey Spencer Phillips,Feldman William B.,Jung Emily H.,D'Andrea Elvira,Kesselheim Aaron S.
Abstract
The FDA's new table of surrogate endpoints used for drug approvals is an important step forward for overseeing the use of biomarkers in clinical trials. Nevertheless, we present several ways in which the table can be improved.
Publisher
Cambridge University Press (CUP)
Subject
Health Policy,General Medicine,Issues, ethics and legal aspects
Reference9 articles.
1. An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
2. 4. Id.
3. 3. US Food and Drug Administration, “Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure,” available at (last visited July 17, 2019).
4. 5. Id.
5. Surrogate End Points in Clinical Trials: Are We Being Misled?
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献